Evidence map›Paper›PMID 30967876›Full record

ArticleFrontiers in immunology2019

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme.

Mijeong Lee, Chanho Park, Jeongmin Woo, Jinho Kim, Inseong Kho, Do-Hyun Nam, Woong-Yang Park, Yeon-Soo Kim, Doo-Sik Kong, Hye Won Lee and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Autologous profiling reveals inter-patient heterogeneity in Vδ2Journal for immunotherapy of cancer · 2025
    Article
  8. Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025
    Review
  9. Review
  10. Article
  11. A GD (Gamma-Delta) type of cancel culture.Immuno-oncology technology · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mijeong LeeDepartment of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, South Korea.
Chanho ParkDivision of Immunobiology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea.
Jeongmin WooSamsung Genome Institute, Samsung Medical Center, Seoul, South Korea.
Jinho KimSamsung Genome Institute, Samsung Medical Center, Seoul, South Korea.
Inseong KhoDivision of Immunobiology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea.
Do-Hyun NamDepartment of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, South Korea.
Woong-Yang ParkDepartment of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, South Korea.
Yeon-Soo KimDepartment of New Drug Discovery and Development, Chungnam National University, Daejeon, South Korea.
Doo-Sik KongInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, South Korea.
Hye Won LeeDepartment of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, South Korea.
Tae Jin KimDepartment of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, South Korea.
Samsung (South Korea) · KRSamsung Medical Center · KRSungkyunkwan University · KRChungnam National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is clinically highly aggressive as a result of evolutionary dynamics induced by cross-talk between cancer cells and a heterogeneous group of immune cells in tumor microenvironment. The brain harbors limited numbers of immune cells with few lymphocytes and macrophages; thus, innate-like lymphocytes, such as γδ T cells, have important roles in antitumor immunity. Here, we characterized GBM-infiltrating γδ T cells, which may have roles in regulating the GBM tumor microenvironment and cancer cell gene expression. V(D)J repertoires of tumor-infiltrating and blood-circulating γδ T cells from four patients were analyzed by next-generation sequencing-based T-cell receptor (TCR) sequencing in addition to mutation and immune profiles in four GBM cases. In all tumor tissues, abundant innate and effector/memory lymphocytes were detected, accompanied by large numbers of tumor-associated macrophages and closely located tumor-infiltrating γδ T cells, which appear to have anti-tumor activity. The immune-related gene expression analysis using the TCGA database showed that the signature gene expression extent of γδ T cells were more associated with those of cytotoxic T and Th1 cells and M1 macrophages than those of Th2 cells and M2 macrophages. Although the most abundant γδ T cells were Vγ9Vδ2 T cells in both tumor tissues and blood, the repertoire of intratumoral Vγ9Vδ2 T cells was distinct from that of peripheral blood Vγ9Vδ2 T cells and was dominated by Vγ9Jγ2 sequences, not by canonical Vγ9JγP sequences that are mostly commonly found in blood γδ T cells. Collectively, unique GBM-specific TCR clonotypes were identified by comparing TCR repertoires of peripheral blood and intra-tumoral γδ T cells. These findings will be helpful for the elucidation of tumor-specific antigens and development of anticancer immunotherapies using tumor-infiltrating γδ T cells.

Indexed as

GlioblastomaLymphocytes, Tumor-InfiltratingReceptors, Antigen, T-Cell, gamma-deltaTumor MicroenvironmentCell Line, TumorDatabases, Nucleic AcidFemaleHumansImmunity, CellularMaleT-LymphocytesReceptors, Antigen, T-Cell, gamma-deltagamma-delta T-cell receptor repertoiregamma-delta T cellsglioblastoma multiformeimmune repertoire sequencingtumor immune microenvironment

Identifiers

PMID30967876
PMCPMC6440384
OpenAlexW2925332771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.